Why are genetically enggineered mouse models (GEMMs) relevant in B-cell lymphoma?
One of the key reasons why oncology clinical trials fail is the limited predictive value of traditional preclinical models, such as long-passaged cell lines or CDX (cell line-derived xenografts). These systems often fail to recapitulate the complexity of the human tumor microenvironment — a limitation that becomes particularly critical in hematologic malignancies like B-cell lymphomas. […]
Breakthrough against aggressive cancers: Combination therapy enhances immunotherapy and extends survival in lung, breast, and melanoma tumors
Research supported by the Spanish Association Against Cancer (AECC) has demonstrated that a novel triple drug combination enhances the efficacy of immunotherapy in animal models of several cancer types, including solid tumors of the lung, breast, melanoma, and glioblastoma. This combination not only acts directly on the tumor but also boosts the immune system’s activity, […]
Lifetime Achievement Award Celebrates Dr. San Miguel’s Landmark Work in Advancing Myeloma Treatments
We are honored to have attended to the European Hematology Association (EHA) Congress in Milan, a key event gathering leaders in hematology from around the world. During the congress, we had the immense privilege of witnessing the Lifetime Achievement Award being presented to Dr. Jesús San Miguel Izquierdo, a truly inspiring figure in hematology and […]
